06/12
Headlines

CytRx Corporation

Investors Watch List : Merck & Co (NYSE:MRK), Activision Blizzard (NASDAQ:ATVI), Brooks Automation (NASDAQ:BRKS), Entergy Corporation (NYSE:ETR), CytRx Corporation (NASDAQ:CYTR)

Chris Lewis03 mins

Merck & Co. Inc. (NYSE:MRK) has been sued by Bristol-Myers Squibb Co (BMY) and Ono Pharmaceutical Co., Ltd. (Japan) (OPHLY) for patent infringement of Bristol-Myers’ novel PD-1 inhibitor, Optivo. Merck recently won the US Food and Drug Administration’s (FDA) approval for its own PD-1 drug, Keytruda. This made the company the first one to enter…

Read More

Today’s Hot List : CytRx Corporation (NASDAQ:CYTR), LipoScience, Inc. (NASDAQ:LPDX), India Fund, Inc. (NYSE:IFN), FreeSeas Inc. (NASDAQ:FREE), Enventis Corporation (NASDAQ:ENVE)

Mark DeFrance02 mins

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & Technology Conference. President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present on Friday, September 12th at 10:45am Pacific Time. CytRx Corporation…

Read More

Today’s Stocks : CytRx Corporation (NASDAQ:CYTR), Advanced Micro Devices, (NYSE:AMD), First Community Bancshares, Inc. (NASDAQ:FCBC), Altra Industrial Motion Corp. (NASDAQ:AIMC), Excel (NYSE:EXL)

Chris Lewis03 mins

CytRx Corporation (NASDAQ: CYTR) a biopharmaceutical research and development company specializing in oncology today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & Technology Conference. President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present on Friday September 12th at 10:45am Pacific Time….

Read More

Trader’s Watch List – Bed Bath (NASDAQ:BBBY) , Walt Disney (NYSE:DIS) , Rexnord (NYSE:RXN) , CytRx (NASDAQ:CYTR) , Eldorado Gold (NYSE:EGO)

Kevin Long03 mins

Analysts at Nomura started coverage on shares of Bed Bath & Beyond (NASDAQ:BBBY) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $65.00 price target on the stock. Nomura’s target price would indicate a potential upside of 6.56% from the company’s current price….

Read More